Another limitation is represented by the clinical and biological heterogenicity of both breast and lung cancer; the choice of a precise histotype (adenocarcinoma) and a molecular subgroup (EGFR mutated) also aims to simplify this heterogeneous landscape. This evidence concerns the gene EGFR and adenocarcinoma.